Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 9/20 | 0.52 |
| ▸ | CA2 | P00918 | 9/20 | 0.52 |
| ▸ | CA9 | Q16790 | 9/20 | 0.52 |
| ▸ | CA12 | O43570 | 5/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.52 |
| ▸ | ELF3 | P78545 | 4/20 | 0.48 |
| ▸ | MED23 | Q9ULK4 | 4/20 | 0.48 |
| ▸ | CA7 | P43166 | 2/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.45 |
| ▸ | HTR3A | P46098 | 3/20 | 0.44 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19669980 | 0.97 | CA1 (0.51) | CA1CA2CA9CA12CA14 | |
| SCHEMBL19365748 | 0.97 | CA1 (0.51) | CA1CA2CA9CA12CA14 | |
| SCHEMBL19361190 | 0.88 | SLC5A2 (0.50) | HTR3A | |
| SCHEMBL16250025 | 0.86 | SLC5A2 (0.50) | HTR3AFKBP1A | |
| SCHEMBL19669062 | 0.86 | SLC5A2 (0.50) | HTR3AFKBP1A | |
| SCHEMBL19365750 | 0.85 | CA1 (0.53) | CA1CA2CA9CA12CA14 | |
| SCHEMBL19365740 | 0.78 | SLC5A2 (0.50) | HTR3A | |
| SCHEMBL19361189 | 0.77 | SIRT5 (0.31) | — | |
| SCHEMBL19862439 | 0.75 | KMT2A (0.41) | CA2CA9 | |
| SCHEMBL16754369 | 0.75 | IDH2 (0.41) | CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-9834558-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834558-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | SIRT1, SIRT3, SIRT2 | CA1 4553/4885CA2 4253/4885CA9 4248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.